Mobile website
Translational Medicine
Research progress of clincal translation on signal pathway and relevant drugs in tumor angiogenesis
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Angiogenesis plays an important role in almost all aspects of tumor biology, including the occurrence, proliferation, progression and metastasis. Accordingly, inhibition of tumor angiogenesis through targeting key molecules in the signal pathways involved in angiogenesis has become a subject of extensive and intensive research in the field of anti-tumor drug development. Amongst these molecules are VEGF/VEGFR, Angiopoietin(Ang)/Tie, platelet derived growth factor, fibroblast growth factor, Delta-like Ligand (DLL4)/Notch, transforming growth factor β, hepatocyte growth factor, and endothelin. A few drugs, such as bevacizumab, sorafinib and sunitinib, targeting angiogenic molecules have been approved by FDA and their clinical use has generated satisfactory results in treating colorectal cancer, renal cell carcinoma, non small cell lung cancer, hepatocellular carcinoma and gastrointestinal stroma tumor; dozens of unapproved drugs in this class are under evaluation in clinical trials. This article aims to review recent advances in both bench-top and translational research on essential signal pathways involved in tumor angiogenesis.
Keywords:
Project Supported:
Clc Number:
